Isolated limb perfusion in primary and recurrent melanoma: Indications and results

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 202-209

  Liénard, Danielle ^a   Eggermont, Alexander M ^b   Kroon, Bin B R ^c   Schraffordt Koops, Heimen ^d   Lejeune, Ferdinand J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Induced hyperthermia; Melanoma; Melphalan; Neoplasm metastasis; Phase II clinical trials; Phase IlI clinical trials; Recombinant interferon gamma; Regional perfusion; Remission induction; Survival rate; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ARTERY CATHETER; ARTERY CATHETERIZATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHEMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEG; LEG EDEMA; LIMB PERFUSION; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MELANOMA; MELPHALAN; PILOT PROJECTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031945557     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<202::AID-SSU3>3.0.CO;2-C     Document Type: Article

References (47)

1. Lejeune FJ, Deloof T, Ewalenko P, et al: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 1983;86:268-276.
2. Stehlin JS Jr: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969;129:305-308.
3. Creech O, Ryan R, Krementz ET: Treatment of malignant melanoma by isolation perfusion technique. J Am Med Assoc 1959;169:339-343.
4. Hoekstra H, Naujocks T, Schraffordt Koops H, et al: Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat 1992;4:301-304.
5. Klaase JM, Kroon BB, van Geel AN, et al: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124-1126.
6. Vrouenraets BC, Kroon BB, Ogilvie AC, et al: Absence of severe systemic toxicity after leakage controlled isolated limb perfusion (ILP) with high-dose TNFα + melphalan [Abstract]. Melanoma Res 1997;7(Suppl 1):S111.
7. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670.
8. Aggarwal BB, Kohr WJ, Hass PE, et al: Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260:2345-2354.
9. Fransen L, Muller R, Marmenout A, et al: Molecular cloning of mouse tumor necrosis factor cDNA and its eukaryotic expression. Nucl Acids Res 1985;3:4417-4429.
10. Pennica D, Hayflick JS, Bringman TS, et al: Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985;82:6060-6064.
11. Old LJ: Tumor necrosis factor (TNF). Science 1985; 230(4726):630-632.
12. Balkwill FR, Lee A, Aldam G, et al: Human tumor xenografts treated with human TNF alone or in combination with Interferon. Cancer Res 1986;46:3990-3993.
13. Fiers W, Brouckaert P, Guisez Y: Recombinant interferon gamma and its synergism with tumor necrosis factor in the human and mouse systems. In Schellekens H, Stewart WE (eds): "The biology of the interferon system". Amsterdam: Elsevier Science; 1985. p. 241-248.
14. Chapman PB, Lester TJ, Casper ES, et al: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942-1951.
15. Sherman ML, Spriggs DR, Arthur KA, et al: Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effect on lipid metabolism. J Clin Oncol 1988;6:344-350.
16. Old LJ: Introduction. In Bonavida B, Granger G (eds): "Tumor necrosis factor: structure, mechanism of action, role in disease and therapy". Basel: Karger; 1990. p. 1-30.
17. Sohmura Y: Antitumor effect of recombinant human tumor necrosis factor alpha and its augmentation in vitro and in vivo. In Bonavida B, Gifford GE, Kirschner H, Old LJ (eds): "Tumor necrosis factor: cachectin and related cytokines". Basel: Karger; 1988. p. 189-195.
18. Manusama ER, Nooijen PT, Stavast J, et al: Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-555.
19. Aggarwal BB, Eessalu TE, Hass PE: Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 1985;318(6047):665-667.
20. Posner M, Liénard D, Lejeune FJ, et al: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic in-transit melanoma [Abstract]. Proc Am Soc Clin Oncol 1994;13:396.
21. Watanabe N, Niitsu Y, Umeno H, et al: Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988;48:650-653.
22. Honess DJ, Bleehen NM: Heat potentitation of melphalan: studies on melphalan transport system. In Overgaard J (ed): "Hyperthermic oncology". Proceedings of the 4th International Symposium on Hyperthermic Oncology; 1984 July 2-6; Arhus, Denmark. Vol 1. Philadelphia: Taylor & Francis; 1984-1985. p. 441-448.
23. Liénard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
24. Liénard D, Lejeune FJ, Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-240.
25. Lejeune FJ: High dose recombinant tumour necrosis factor (rTNF-alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995;31A:1009-1016.
26. Liénard D, Eggermont A, Schraffordt Koops H, et al: The use of TNF in isolated limb perfusion for treatment of locally advanced melanoma: an update [Abstract]. Cambridge Symposium on TNF and Related Cytokines; 1996 Mar 10-16; Hilton Head Island, South Carolina, p. 12.
27. Liénard D, Eggermont AM, Schraffordt Koops H, et al: Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994;4(Suppl 1):S21-S26.
28. Eggimann P, Chiolero R, Chassot PG, et al: Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995;107:1074-1082.
29. Lejeune F, Liénard D, Eggermont AM, et al: Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma [Review]. Circ Shock 1994; 43:191-197.
30. Eggermont AM, Schraffordt Koops H, Liénard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [comments in: J Clin Oncol 1996;14:2627-2630; J Clin Oncol 1997;15:2174-2175]. J Clin Oncol 1996;14:2653-2665.
31. Sijens PE, Eggermont AM, van Dijk PV, Oudkerk M: 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed 1995;8:215-224.
32. Nieweg OE, Pruim J, Hoestra HJ, et al: Positron emission tomography with fluorine-18-fluorodeoxyglocose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 1994;35:90-92.
33. Renard N, Liénard D, Lespagnard L, et al: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular hish-dose rumor necrosis factor alpha (rTNF alpha). Int J Cancer 1994;57:656-663.
34. Renard N, Nooijen PT, Schalkwijk L, et al: VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995;176:279-287.
35. Burke-Gaffney A, Keenan AK: Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology 1993;25:1-9.
36. Fraker D: What is the best regional therapy ? [Abstract]. Melanoma Res 1997;7(Suppl 1): S42.
37. Di Filippo F, Anza M, Rossi CR, et al: Hyperthermic antiblastic perfusion with TNF-alpha and LPAM in patients with stage II, HIA and IHAB limb melanoma. Melanoma Res 1997;7(Suppl 1):S32-33.
38. Gerain J, Liénard D, Ewalenko P, Lejeune FJ: High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. Cytokine 1992;4:585-591.
39. Hill S, Thomas JM: Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res 1994;4(Suppl 1):S31-S34.
40. Vaglini M, Santinami M, Manzi R, et al: Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994;4(Suppl 1):S35-S38.
41. Fraker DL, Alexander HR, Andrich M, Rosenberg SA: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, rumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-489.
42. Schraffordt Koops H, Kroon BB, Oldhoff J, Hoekstra HJ: Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World J Surg 1992;16:241-245.
43. Franklin HR, Schraffordt Koops H, Oldhoff J, et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988;6:701-708.
44. Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984;200:764-768.
45. Ghussen F, Kruger W, Groth W, et al: [Randomized melanoma study of perfusion of the extremities. Results of treatment 21/2 years after premature discontinuation]. Chirurg 1986;57:619-623. (Ger).
46. Ghussen F, Kruger I, Groth W, Stutzer H: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988;61:654-659.
47. Wieberdink J, Benckhuysen C, Braat RP, et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.